Indeed, pharmacological inhibition of Epac by treatment with the Epac specific inhibitor 09 (ESI-09) decreases the adhesion of cells to their substratum and disrupts microtubules distribution and AKAP9 localization, contributing to reduced breast cancer cell migration [78]. Here, RAPGEF3 is linked to breast cancer.